---
document_datetime: 2026-01-05 13:29:21
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/alymsys-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: alymsys-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.951092
conversion_datetime: 2026-01-06 07:24:30.284397
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Alymsys

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number         | Scope   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------------|---------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| PSUR / EMA/PSUR/0000274402 | - -     | 16/10/2025                          | 18/12/2025                                  | SmPC                             | Variation |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                       | glomerular microangiopathy reported in the literature, including in some cases a positive de-challenge and in view of a plausible mechanism of action, the PRAC considers a causal relationship between bevacizumab and hyaline occlusive glomerular microangiopathy is at least a reasonable possibility. The PRAC concluded that the product information of products containing bevacizumab should be amended accordingly.   |            |     |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type II / EMA/VR/0000272167 | B.I.e) Design Space and post-approval change management protocols - B.I.e.2 Introduction of a post approval change management protocol related to the active substance - Accepted                                                                                                                                                                                                                                              | 09/10/2025 | N/A |
| Variation type IB / EMA/VR/0000276462 | This was an application for a group of variations. B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.d Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) - Accepted                                                             | 03/07/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                       | parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.c Addition of a new specification parameter to the specification with its corresponding test method - Accepted B.I.d.1 Change in the re-test period/storage period or storage conditions of the active substance where no Ph. Eur. Certificate of Suitability covering the retest period is part of the approved dossier - B.I.d.1.c Change to an approved stability protocol - Accepted B.II.f.1 Change in the shelf-life or storage conditions of the finished product - B.II.f.1.e Change to an approved stability protocol - Accepted   |            |     |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000269765 | This was an application for a group of variations. B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.z Other changes - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                           | 26/05/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                       | parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.d Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) - Accepted                                                                                                                                                                                                                                                                                                                                 |            |     |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000269362 | This was an application for a group of variations. B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.a Minor change in the manufacturing process - Accepted B.I.b) Control of active substance - B.I.b.z If information on the level of testing performed by the FP manufacturer on receipt of the AS batches is already present in the approved registration dossier, the applicant is advised to apply for a Type IB (B.I.b.z) variation to remove this information from the dossier. - Accepted | 22/05/2025 | N/A |
| Variation type IA / EMA/VR/0000264674 | This was an application for a group of variations. B.I.b.2 Change in test procedure for active                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 08/04/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                       | substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an   |            |     |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000247279 | B.II. FINISHED PRODUCT - B.II.z To update Module 3.2.A.1 for a biotech medicinal product - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 25/02/2025 |     |
| Variation type IB / EMA/VR/0000244798 | B.I.e.5 Implementation of changes foreseen in an approved change management protocol - B.I.e.5.c Implementation of a change for a biological/immunological medicinal product - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                   | 12/02/2025 | N/A |